Actively Recruiting
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Led by Taizhou Mabtech Pharmaceutical Co.,Ltd · Updated on 2025-05-22
30
Participants Needed
1
Research Sites
175 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
CONDITIONS
Official Title
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 6 and 17 years, any gender
- Diagnosed with moderate to severe active Crohn's disease according to expert consensus
- Patient and/or guardian signed informed consent and research agreement
- Receiving Infliximab for the first time
You will not qualify if you...
- Contraindications to Infliximab such as severe infection, active tuberculosis, lymphoma or other cancers, moderate to severe heart failure, or allergies to murine proteins or Infliximab components
- Use of other anti-TNF-alpha biological drugs or other biological treatments
- Planned or recent live vaccination within 3 months before or during treatment
- Participation in other clinical studies within 3 months before signing consent
- Investigator judgment deems patient unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Children's Hospital, Capital Medical University
Beijing, China
Actively Recruiting
Research Team
W
Wu Jie
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here